VANCOUVER, BC, February 2, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) is pleased to announce that it has finalized an exclusive licensing agreement with UBC for a patented and potentially breakthrough AI-based sepsis diagnostic technology. The technology, developed under the leadership of a leading microbiologist at UBC and the company’s founding director and chief operating officer, Dr. Robert E. W. Hancockenables early and accurate diagnosis of deadly sepsis, which caused 11 million deaths worldwide in 20171 and is also a major contributing factor to COVID-19-related morbidity2. The patent covers the subject of a recently published academic article on January 10, 2022in the prestigious medical journal, eBioMedicine3.
The article demonstrates that sepsis, a difficult disease to diagnose due to the wide variability of symptoms and findings, can be divided into five distinct subtypes/endotypes based on the underlying biological mechanisms that drive the disease. The research behind the paper confirms that patients hospitalized with life-threatening COVID-19 also belong to these same endotypes, indicating that many COVID-19 patients have severe sepsis. Two endotypes in particular were associated with more severe sepsis and associated organ failure, and patients belonging to these two subtypes were more likely to die. The most severe form of sepsis, occurring in up to half of all hospitalized patients with COVID-19, can lead to multi-organ failure, the need for mechanical ventilation and, in many cases, death. Additionally, many patients who recover from severe sepsis suffer from chronic medical conditions that are very similar to those that afflict patients who suffer from long-term COVID-19 illness, called long-term COVID. Being able to classify sepsis into the five sepsis endotypes could provide key information to physicians regarding underlying disease mechanisms and help guide personalized treatment options for patients most at risk for severe sepsis.
The company is tackling this disease head-on with its new diagnostic test called SepsetEmergencies ™. The test detects the dysfunctional immune response underlying sepsis the moment patients first enter the emergency room. The test is a blood-based gene expression test that is simple to perform, and results are obtained in about an hour in the emergency room or intensive care unit. Current diagnostic tools provide results after approximately 24 to 36 hours, which often delays the start of treatment. SeptemberEmergencies is designed to allow doctors to quickly predict the severity of the disease and thus define better and more immediate treatment options for the patient. The refinement of the technology is based on data from more than 200 patients. The patent licensing agreement gives Asep Inc.’s subsidiary, Sepset Biosciences Inc., the exclusive rights to develop sepsis severity endotypes into a diagnostic test and bring the test to market.
dr. Robert E. W. Hancock added: “This technology will allow us to have a major impact on the lives of patients who contract this deadly syndrome. Early and accurate diagnosis is key to saving lives and we expect this technology to be widely used in hospitals and clinics around the world. “
Rudy MazzocchiPresident and CEO of Asep Inc. said, “We are extremely pleased with the continued partnership with UBC and their valuable role in expanding our patent portfolio and advancing our technologies as we plan the initiation of clinical studies to support a regulatory filing for commercial approval later this year. We own a controlling interest in Sepset Biosciences Inc. and the subsidiary is well funded and responsible for bringing this breakthrough technology to market quickly and efficiently.
Sepsis is the body’s dysfunctional response to infection and is very common, occurring in 49 million people worldwide. Recently, the situation has worsened since sepsis is the cause of death for most patients who die from COVID-19. Sepsis is extremely complex and early symptoms are relatively nonspecific, including fever, fatigue, hyperventilation and rapid heart rate – symptoms that can also occur in other illnesses. The most severe form of the disease, which occurs in up to half of all patients with suspected sepsis, leads to multiple organ failure and, in 23% of cases, death. Current diagnostic tools provide results after approximately 24 to 36 hours, which often delays the start of treatment.
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Inc. is dedicated to solving antibiotic failure by developing new solutions to major unmet medical needs. It represents the consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) which are in the advanced development of proprietary diagnostic tools, enabling early and rapid identification of severe sepsis, and therapeutic agents broad-spectrum to treat multidrug-resistant biofilm infections. The diagnostic technology involves a patient’s gene expression signature that predicts severe sepsis, one of the major diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetEmergencies the test is identified in blood and evaluable by nucleic acid amplification/PCR technologies. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate therapies and reduce mortality and morbidity.
ABT Innovations Inc.’s peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedics, etc.), representing two-thirds of all infections, anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.
This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. Forward-looking statements contained in this press release include, but are not limited to, the successful completion of clinical testing of our Sepsis diagnostic test and its anticipated filing for regulatory approval; conducting preclinical studies on our lead drug, in the hope that this will lead to accelerated clinical trials; the ability of our diagnostic test kit to diagnose sepsis within the stated time frames; that early detection and diagnosis of sepsis will save costly and unnecessary antibiotic treatment; and that timely test results will allow physicians to make more effective treatment decisions. Various assumptions have been used in drawing the conclusions or making the predictions contained in the forward-looking statements throughout this press release, including the assumption that our diagnostic test kits will be adopted and used by physicians to diagnose and treat sepsis. Forward-looking statements are based on the opinions and estimates of management as of the date they are made and are subject to various risks (including the risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021, and Asep Inc.’s most recent management discussion and analysis) available for review under the company profile at www.sedar.com and the uncertainties and other factors that could cause events or actual results differ materially from those projected in the forecast. statements. Asep Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires it.
- Rudd, KE et al. Global, regional and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395, 200-211 (2020)
- Vincent, J.-L. COVID-19: it’s all about sepsis. Future Microbiol 10.2217/fmb-2020-0312 doi: 10.2217/fmb-2020-0312
- Baghela, A. et al. Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures. eBioMedicine January 10, 2022
SOURCEASEP Medical Holdings Inc.